Concarlo Therapeutics Email Format
Biotechnology ResearchNew York, United States11-50 Employees
Concarlo Therapeutics is a biotechnology research company headquartered in Brooklyn, New York, founded in 2016. It pursues precision oncology by diagnosing and treating cancer through targeting the cellular pathway linked to p27Kip1. The firm highlights its IpY concept as an inhibitor designed to overcome CDK2 resistance, target p27, and inhibit both CDK4 and CDK2. In 2022, Concarlo announced leadership appointments, naming Vadim Shepel as Chief Business & Operating Officer and Dr. Allamneni as Chief Development Officer, signaling ongoing development of its pipeline from discovery through clinical stages. Operatively, the company sits within the biotechnology research sector with a focus on innovative approaches to drug resistance via the p27Kip1 pathway.